Tibotec, Gilead to develop HIV combinations
Tibotec Pharmaceuticals and Gilead Sciences Inc. (NASDAQ:GILD) agreed to develop and commercialize a fixed-dose HIV treatment combining Tibotec's marketed Prezista darunavir and Gilead's investigational cobicistat. Tibotec would be responsible for formulation, manufacturing, registration and commercialization of the combination worldwide. Gilead, which would be eligible for royalties, would retain rights for cobicistat as an individual product and for use in combination with other products. Tibotec is a unit of Johnson & Johnson (NYSE:JNJ).
The companies are also negotiating terms for development of a single-tablet HIV regimen combining Tibotec's Prezista with Gilead's marketed Emtriva emtricitabine, cobicistat and its investigational GS 7340. Gilead would be responsible for worldwide development and commercialization. The companies said the Prezista/cobicistat partnership is contingent upon the signing of a deal for the Prezista/Emtriva/GS-7340/cobicistat combination. ...